The return of the IP securitisation

A $250 miliion securitisation of future royalties generated from a yet-to-be approved hepatitis C drug being developed by Vertex Pharmaceuticals has got the Financial Times quite excited. The deal, being arranged by Morgan Stanley, will see Johnson …

Unlock unlimited access to all IAM content